Want to see IN:AARTIPHARM full AI Analyst Report?

Aarti Pharmalabs Limited (AARTIPHARM) Price & Analysis

2 Followers

AARTIPHARM Stock Chart & Stats

₹842.40

₹9.55(1.45%)

At close: Jan 09 4:00 PM EST

₹842.40

₹9.55(1.45%)

Day’s Range― - ―

52-Week Range₹583.85 - ₹1,001.55

Previous CloseN/A

Volume141.60K

Average Volume (3M)49.83K

Market Cap

₹75.61B

Enterprise Value₹60.87B

Total Cash (Recent Filing)₹96.16M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)35.9

Beta0.86

Next Earnings

Oct 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.42%

Share Statistics

EPS (TTM)23.51

Shares Outstanding90,679,810

10 Day Avg. Volume34,655

30 Day Avg. Volume49,830

Financial Highlights & Ratios

PEG Ratio-0.92

Price to Book (P/B)2.71

Price to Sales (P/S)3.16

P/FCF Ratio-30.89

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Regulated API And Intermediate ManufacturingA business focused on regulated, high-purity APIs and pharmaceutical intermediates serves essential inputs in pharmaceutical production. Customer qualification and compliance requirements can support recurring demand and make established manufacturing capabilities relevant across multiple product cycles and end markets.

Historically Solid ProfitabilityHealthy operating and net margins across FY2023–FY2025 indicate that the company has demonstrated the ability to convert pharmaceutical and specialty chemical sales into profits. Revenue expansion through FY2025 also supports a record of scalable operations, despite later earnings pressure.

Positive Operating Cash GenerationPositive operating cash flow shows that the underlying business has generated cash from operations rather than relying solely on accounting earnings. Combined with a reasonable equity base, this provides some internal support for ongoing operations and investment, even though free cash flow has recently weakened.

Bears Say

FY2026 Revenue And Earnings DeclineThe FY2026 deterioration signals weaker demand, mix, or operating conditions than in the prior year and reduces confidence in near-term earnings consistency. A simultaneous revenue decline and sharp net-income fall can also make recovery dependent on renewed volume growth or margin improvement.

Materially Higher LeverageThe sharp increase in borrowings raises the company’s financial obligations while profitability is under pressure. Higher leverage can constrain capital allocation, increase sensitivity to earnings volatility, and leave less balance-sheet flexibility for investment or absorbing weaker operating performance over the coming quarters.

Negative Free Cash FlowMeaningfully negative free cash flow indicates that investment or working-capital requirements are absorbing the cash produced by operations. If sustained, this can increase reliance on external funding, limit financial flexibility, and make growth more dependent on successful cash conversion in future periods.

Aarti Pharmalabs Limited News

Aarti Pharmalabs Confirms SEBI-Compliant Dematerialisation for September Quarter

An update from Aarti Pharmalabs Limited ( ($IN:AARTIPHARM) ) is now available. Aarti Pharmalabs Limited has submitted a...

14d ago

Aarti Pharmalabs Publishes AGM and Annual Report Notices for FY 2025-26

An announcement from Aarti Pharmalabs Limited ( ($IN:AARTIPHARM) ) is now available. Aarti Pharmalabs Limited has notified the...

2M ago

Aarti Pharmalabs Publishes Q1 FY27 Financial Results in Newspapers

Aarti Pharmalabs Limited ( ($IN:AARTIPHARM) ) has shared an announcement. Aarti Pharmalabs Limited announced that its standalone and...

3M ago

Aarti Pharmalabs Boosts Equity Capital Through Employee Stock Option Allotment

Aarti Pharmalabs Limited ( ($IN:AARTIPHARM) ) has shared an update. Aarti Pharmalabs Limited has increased its paid-up equity...

4M ago

Aarti Pharmalabs Clears FY26 Results, Recommends Dividend and Strengthens Governance

Aarti Pharmalabs Limited ( ($IN:AARTIPHARM) ) has shared an update. Aarti Pharmalabs Limited’s board has approved the audited...

5M ago

Aarti Pharmalabs Clears FY26 Results, Proposes Dividend and Strengthens Governance Bench

Aarti Pharmalabs Limited ( ($IN:AARTIPHARM) ) has provided an announcement. Aarti Pharmalabs Limited’s board has approved the audited...

5M ago

Aarti Pharmalabs Posts Q3 FY26 Earnings Call Recording Online

Aarti Pharmalabs Limited ( ($IN:AARTIPHARM) ) has issued an update. Aarti Pharmalabs Limited has announced that the audio...

8M ago

Aarti Pharmalabs Schedules Q3 FY26 Earnings Call for 10 February

Aarti Pharmalabs Limited ( ($IN:AARTIPHARM) ) just unveiled an announcement. Aarti Pharmalabs Limited has scheduled an earnings conference...

9M ago

Aarti Pharmalabs Reports Stable Financial Performance for H1 2025

Aarti Pharmalabs Limited ( ($IN:AARTIPHARM) ) has provided an announcement. Aarti Pharmalabs Limited announced its unaudited financial results...

12M ago

Aarti Pharmalabs Submits SEBI Compliance Certificate for Q3 2025

Aarti Pharmalabs Limited ( ($IN:AARTIPHARM) ) just unveiled an update. Aarti Pharmalabs Limited, a company involved in the...

1y ago

AARTIPHARM FAQ

What was Aarti Pharmalabs Limited’s price range in the past 12 months?

Aarti Pharmalabs Limited lowest stock price was ₹583.85 and its highest was ₹1001.55 in the past 12 months.

What is Aarti Pharmalabs Limited’s market cap?

Aarti Pharmalabs Limited’s market cap is ₹75.61B.

When is Aarti Pharmalabs Limited’s upcoming earnings report date?

Aarti Pharmalabs Limited’s upcoming earnings report date is Oct 28, 2026 which is in 5 days.

How were Aarti Pharmalabs Limited’s earnings last quarter?

Aarti Pharmalabs Limited released its earnings results on Aug 07, 2026. The company reported ₹8.397 earnings per share for the quarter.

Is Aarti Pharmalabs Limited overvalued?

According to Wall Street analysts Aarti Pharmalabs Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Aarti Pharmalabs Limited pay dividends?

Aarti Pharmalabs Limited pays a Semiannually dividend of ₹2 which represents an annual dividend yield of 0.42%. See more information on Aarti Pharmalabs Limited dividends here

What is Aarti Pharmalabs Limited’s EPS estimate?

Aarti Pharmalabs Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aarti Pharmalabs Limited have?

Aarti Pharmalabs Limited has 90,679,810 shares outstanding.

What happened to Aarti Pharmalabs Limited’s price movement after its last earnings report?

Aarti Pharmalabs Limited reported an EPS of ₹8.397 in its last earnings report. Following the earnings report the stock price went down -0.732%.

Which hedge fund is a major shareholder of Aarti Pharmalabs Limited?

Currently, no hedge funds are holding shares in IN:AARTIPHARM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.